(Shenzhen, China, October 30, 2018, PRNewswire=Yonhap News) MGI, a subsidiary of BGI Group, introduced the latest model of gene sequencer, the MGISEQ-T7, which features significantly improved speed, throughput, and flexibility, at the 13th International Conference on Genomics (ICG-13) held in Shenzhen. As the most powerful MGI sequencer to date, the MGISEQ-T7 is built with an innovative quadruple flow-cell staging system in which one to four flow cells operate simultaneously and independently during a single run. MGI's proprietary technology used in the T7 can further improve accuracy and efficiency through upgrades to the flow cells, fluid, biochemical, and optical systems. MGISEQ-T7, a supercomputer for the life science industry, raises the production capacity of sequencers to a new level with a daily data production capacity of up to 6 Tb.

Jian Liu, Executive Vice President of MGI, unveiled MGISEQ-T7

"Customers have now secured complete flexibility for a wide range of sequencing through an all-in-one device," said MGI CEO Feng Mu.

The innovations of MGISEQ-T7 are as follows.

A unique Quad-Flowcell platform supporting the independent operation of 1 to 4 chips

The quad-flow cell platform enables multiple flow cells with different read lengths and applications to be processed independently at any time in a single operation. This platform supports total genome sequencing, ultra-high reliability true genome sequencing, and large-panel oncogene detection.

50% increase in sequencing speed

The MGISEQ-T7 operates much faster than other sequencers to date. The PE150 is completed within 24 hours of full loading.

20% increase in single-chip density

With a 20% increase in chip density, the MGISEQ-T7 can produce terabyte-level data on a single chip.

Partners and customers around the world who have used the MGI platform, including researchers at RIKEN, Mayo Clinic, Karolinska Institutet , Curetis, and Weill Cornell Medicine, have recognized the distinct advantages of this product.

Dr. George Church, a professor of genetics and health sciences at Harvard and MIT, said, "MGI is the first company capable of achieving essentially error-free genome sequencing at an affordable price."

Boasting ultra-high speed and ultra-high throughput, the MGISEQ-T7 surpasses the limitations of next-generation sequencers, capable of completing WGS of up to 60 human genomes per day. As the MGISEQ-T7 can complete 10,000 genome sequences per year, it will accelerate the development of nationwide genomics projects.

BGI Group President Jian Wang stated, "This research will bring benefits to humanity around the world," adding, "MGI's mission is to help humanity live healthier and better lives."